GlassScriptPhysician profile
Paul A Lawrence
NPI 1376630707
$3,235.18
in general payments reported to CMS, 2019-2025
35 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,134 · 2020: $366 · 2021: $14.53 · 2022: $290 · 2023: $428 · 2024: $540 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,429.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $485.80 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $379.07 | 2019-2025 | Airsupra, Farxiga, Andexxa |
| Pfizer INC. | $327.20 | 2019-2025 | |
| Amgen INC. | $217.14 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $205.66 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.95 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $136.97 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $123.29 | 2019-2020 | |
| Lilly USA, LLC | $110.77 | 2019-2024 | Jardiance, Baqsimi, Lyumjev |
| Merck Sharp & Dohme LLC | $94.91 | 2019-2023 | Verquvo, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.94 | 2019-2025 | Xifaxan, Trulance |
| Xeris Pharmaceuticals, INC. | $65.98 | 2023-2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $61.55 | 2019-2023 | Veozah, Myrbetriq |
| Abbott Laboratories | $61.40 | 2019-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Amarin Pharma, INC. | $60.14 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $52.51 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $48.17 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $46.71 | 2019-2020 | |
| Glaxosmithkline, LLC. | $44.30 | 2019-2025 | Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.02 | 2024-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $41.05 | 2022 | |
| Alexion Pharmaceuticals, INC. | $40.72 | 2019-2023 | Strensiq |
| E.R. Squibb & Sons, L.L.C. | $34.94 | 2024 | Eliquis |
| Abiomed | $30.96 | 2024 | Impella |
| Arbor Pharmaceuticals, INC. | $30.62 | 2019-2020 | |
| Allergan, INC. | $29.11 | 2019-2020 | |
| Grifols USA, LLC | $28.85 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.89 | 2019 | |
| Sumitomo Pharma America, INC. | $23.03 | 2025 | Gemtesa |
| Corcept Therapeutics | $21.58 | 2025 | Korlym |
| Mylan Specialty L.P. | $20.90 | 2019 | |
| Dexcom, INC. | $19.01 | 2024 | Dexcom G6 Transmitter |
| Paratek Pharmaceuticals, INC. | $18.99 | 2022 | |
| Axsome Therapeutics, INC. | $18.98 | 2025 | Auvelity |
| Exact Sciences Corporation | $16.07 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.